Предварительные результаты клинических испытаний Имутерана — нового препарата для биотерапии рака
Елена Владимировна Артамонова, Liudmila V Manziuk, А. Ю. Барышников et al. · Российский биотерапевтический журнал · 2003
Application of monoclonal antibodies (МАВ) is a new perspective branch of cancer therapy. One of such therapeutic agents is Imuteran — an original Russian drug, created on the base of the substance of ICO-25 МАВ obtained to MUC-l epitope. Preclinical studies demonstrated their high specificity, significant anti-cancer activity in vitro and in vivo and low ICO-25 toxicity. Clinical trials of Imuteran for phase-I were carried out on 10 patients with disseminated tumors. Escalation of single doses was conducted according to the modified Fibonacci scale from the starting dose (5mg— 100%) up to maximum (46.25 mg — 925%). The main side effect was hypersensitivity. The following regimen for Imuteran injection was recommended for phase-II clinical trials: 35 mg (700% of the starting dose) i.v. in drops 1 time per week — 4 injections with dexametason and dimedrol premedications. At present 3 patients are included in phase-II, who have received 4 treatment courses. The results were assessed in 2 patients (process stabilization was noted). There were no side effects at drug injection after premedication. The study is in process.
Cited by 0 works.